Mostrando 501 - 520 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.26s Limitar resultados
  1. 501
    “…BACKGROUND: Conflicting data exist about the prevalence of HER-2/neu overexpression in colorectal cancer ranging from 0 to 83 %. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  2. 502
    por Nahta, Rita, Esteva, Francisco J
    Publicado 2006
    “…We also discuss novel therapies that may improve the efficacy of trastuzumab, and that offer hope that the survival of breast cancer patients with HER2-overexpressing tumors can be vastly improved.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  3. 503
  4. 504
  5. 505
  6. 506
  7. 507
  8. 508
    por Murphy, Conleth G, Modi, Shanu
    Publicado 2009
    “…Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Texto
  9. 509
    por Lorusso, Vito
    Publicado 2008
    “…Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. …”
    Enlace del recurso
    Enlace del recurso
    Texto
  10. 510
  11. 511
    “…Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight. In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastroesophageal adenocarcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  12. 512
  13. 513
    “…In addition, both molecules suppressed HRG-induced HER3 and HER2 phosphorylation in MCF-7 cells, as well as HER3 phosphorylation in constantly HER2-activated SKBR-3 cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 514
    “…This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of HER2 targeted therapy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 515
    por Mortenson, Eric D, Fu, Yang-Xin
    Publicado 2014
    “…Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu therapy also requires CD4(+) T cells and CD40/CD40L signaling within the tumor microenvironment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 516
  17. 517
    “…BACKGROUND: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 518
    “…ERBB3/HER3 is emerging as a molecular target for various cancers. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 519
  20. 520
Herramientas de búsqueda: RSS